(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/buy_a_domain.png

Buy and register domain names online from CRWE Domains. Web hosting, spam-free email, web marketing, secure SSL Certificates and more

www.crwedomains.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






125 Result: Surgery

Shire's First Prescription Eye Drop, Xiidra(TM) (lifitegrast ophthalmic solution) 5% Is Now Available in the U.S.

August 29th, 2016

Xiidra is the onlyprescription eye drop approved by the U.S. FDA for the treatment of both signs and symptoms of dry eye disease Resources are available to support patients seeking information regarding coverage and savings offers Xiidra is t. Read more

Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show

August 29th, 2016

1. Dramatic Decrease in Prostate Cancer and 2. Major Reduction in Need For BPH Prostate Surgery HASBROUCK HEIGHTS, N.J. / CRWE PRESS RELEASE / August 29, 2016 - Nymox Pharmaceutical Corporation (NASDAQ:NYMX) lead drug fexapotide which has been . Read more

Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe

August 22nd, 2016

LOS ANGELES, Calif. / CRWE PRESS RELEASE / August 22, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the Marketing Authorization Application (MAA) for neratinib has been validated by the European Medicines A. Read more

Medtronic Completes $20 Million Second Tranche Investment In Mazor Robotics

August 15th, 2016

CAESAREA, Israel / CRWE PRESS RELEASE / August 15, 2016 – Mazor Robotics Ltd. (TASE: MZOR; NASDAQGM: MZOR), a pioneer and a leader in the field of surgical guidance systems, today announced the completion of the second tranche of the equity inv. Read more

EyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammation and Pain in Cataract Surgery Patients

August 01st, 2016

WALTHAM, Mass. / CRWE PRESS RELEASE / Aug. 01, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing produ. Read more

ONIVYDE(R) Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas who have Progressed Following Gemcitabine based Therapy

July 25th, 2016

The positive opinion is based on a pivotal Phase 3 study showing that ONIVYDE combined with chemotherapy significantly increased overall survival (OS) in patients with metastatic pancreatic cancer after previous gemcitabine based therapy Zug, Swit. Read more

Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)

July 21st, 2016

LOS ANGELES, Calif. / CRWE PRESS RELEASE / July 21, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced updated results from the Phase III clinical trial of Puma's investigational drug PB272 (neratinib) for t. Read more

Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

July 21st, 2016

LOS ANGELES, Calif. / CRWE PRESS RELEASE / July 21, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candida. Read more

VBI Vaccines Announces Medulloblastoma Immunotherapy Program

June 16th, 2016

Cambridge, Massachusetts / CRWE PRESS RELEASE / June 16, 2016 - VBI Vaccines Inc. (Nasdaq: VBIV and TSX: VBV) (“VBI”) today announced that it is developing a novel therapeutic vaccine candidate for medulloblastoma. The Meghan Rose Bradley. Read more

Catabasis Pharmaceuticals Presents Positive Pre-Clinical Data at Digestive Disease Week 2016; Data Support CAT-2054, a Phase 2 Asset, as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH)

May 22nd, 2016

CAMBRIDGE, MA / CRWE PRESS RELEASE / May 21, 2016 - Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced positive pre-clinical data supporting CAT-2054 as a potential treatment for nonalcoholic st. Read more

NOVADAQ Announces Fourth Quarter 2015 Preliminary Unaudited Revenues and Issues 2016 Revenue Guidance

January 11th, 2016

Toronto, Ontario / CRWEPRESSRELEASE / January 11, 2016 - Novadaq Technologies Inc. (“NOVADAQ” or the “Company”) (NASDAQ:NVDQ; TSX:NDQ), the leading developer and provider of clinically relevant fluorescence imaging solutions f. Read more

CEL-SCI Corporation Summarizes Significant Accomplishments in 2015 and Positive Momentum for 2016

January 08th, 2016

Vienna, VA / CRWEPRESSRELEASE / January 8, 2016 -- The following letter is being released by CEL-SCI Corporation (NYSE MKT: CVM) to its shareholders: Dear Fellow Shareholders: As CEL-SCI shareholders most of you have been following the progress. Read more

FDA approves Bridion to reverse effects of neuromuscular blocking drugs used during surgery

December 15th, 2015

First drug approved in new class of medications December 15, 2015 - The U.S. Food and Drug Administration today approved Bridion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium b. Read more

Veracyte Announces Positive Coverage Policy for the Afirma(R) Gene Expression Classifier from Health Care Service Corporation (HCSC)

December 14th, 2015

Additional Blues Plan Issues Positive Coverage Decision for the Afirma GEC; Two More Sign In-Network Contracts SOUTH SAN FRANCISCO, Calif. / CRWEPRESSRELEASE / December 14, 2015 - Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics co. Read more

Trevena Announces FDA Grant of Fast Track Designation to Oliceridine (TRV130)

December 03rd, 2015

King of Prussia, PA / CRWEPRESSRELEASE / December 03, 2015 - Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced th. Read more

Load More Content